Name: Debt to Equity

Definition: Debt to equity shows how much debt the company uses compared to the amount invested by its owners. It’s a bit like comparing your mortgage to your house down payment. Higher ratios suggest the business is comfortable borrowing to grow — which can boost returns in good times, but adds risk if conditions worsen. Lower ratios signal a more conservative, steady approach.

Interpretation:
• In '2023', NEOG's debt to equity was 0.28, showing the balance between debt financing and shareholders' equity. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2023' stood at 0.05.
• In '2024', NEOG's debt to equity was 0.28, showing the balance between debt financing and shareholders' equity. The increase compared to '2023' may signal growing financial pressure. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2024' stood at 0.06. Industry average increased by 0.01 compared to previous year.
Overall, NEOG's debt to equity has remained generally stable over the past 2 years.

Formula: Debt to Equity = Total Debt / Shareholders' Equity

Good Range: Below 1.0 is conservative; 1-2 is common depending on industry.